{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 89,
        "end": 92
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 107,
        "end": 111
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 243,
        "end": 264
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 253,
        "end": 257
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 73,
        "end": 85
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 101,
        "end": 133
      }
    },
    {
      "id": "T11",
      "obj": "Chemical",
      "span": {
        "begin": 101,
        "end": 115
      }
    },
    {
      "id": "T12",
      "obj": "Disease",
      "span": {
        "begin": 186,
        "end": 190
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "21955998_9",
  "text": "In conclusion , this analysis provides confirmation that , compared with chemotherapy or BSC alone , anti- EGFR mAb with chemotherapy or BSC reduces the risk of progression and death of mCRC and that this benefit is seen only in patients with wild-type KRAS tumors ."
}
